指南与共识乳腺癌

根据2007年和2013年美国临床肿瘤学会/美国病理学家学会指南推荐对乳腺癌人表皮生长因子受体2检测的比较分析

Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations.
指南 / 共识 · J Clin Oncol · 2017-04-26

该研究比较了2013年更新与2007年美国临床肿瘤学会/美国病理学家学会乳腺癌人表皮生长因子受体2(HER2)检测指南对大型区域参考实验室检测模式和判读的影响。2012年与2014年各12个月期间,检测样本量增加(2,201例 vs 2,558例患者;2,278个 vs 2,659个肿瘤),HER2阳性率保持恒定(15.7% vs 15.5%),6个月内重复检测数增加超过一倍(122/2,201 [5.5%] vs 302/2,558 [11.8%];P < .001),免疫组织化学(IHC)2+肿瘤比例显著降低(20.3% vs 25.3%;P < .001),而未明确HER2状态(IHC和原位杂交均为 equivocal)的患者比例显著升高(4/2,278 vs 90/2,660;P < .001)。结论认为2013年更新未影响总体HER2阳性率或适合HER2靶向治疗的患者比例,但检测和重复检测比例增加,原位杂交(ISH)不确定患者数增加;该组靶向治疗的获益未被证实,因此不应考虑对该类患者进行靶向治疗,并应在未来指南更新中重新定义。

要点

  • 2012年至2014年检测样本量增加(2,201例 vs 2,558例患者;2,278个 vs 2,659个肿瘤),HER2阳性率保持恒定(15.7% vs 15.5%)。
  • 6个月内重复检测数增加超过一倍(122/2,201 [5.5%] vs 302/2,558 [11.8%];P < .001)。
  • IHC 2+肿瘤比例显著降低(20.3% vs 25.3%;P < .001),而未明确HER2状态患者比例显著升高(4/2,278 vs 90/2,660;P < .001)。

核心结论

  • 2013年美国临床肿瘤学会/美国病理学家学会乳腺癌HER2检测指南更新未影响总体HER2阳性率或适合HER2靶向治疗的患者比例。
  • 检测和重复检测比例增加,原位杂交(ISH)不确定患者数增加。
  • 该不确定组靶向治疗的获益未被证实,因此不应考虑对该类患者进行靶向治疗,并应在未来指南更新中重新定义。

研究设计与样本

  • 从本实验室信息系统选取两个12个月期间(2012年和2014年)进行乳腺癌生物标志物评估的HER2检测评分患者病例。
  • 比较检测数量、标本类型、HER2阳性和不确定患者病例比例以及后续切除标本重复检测数。

主要发现

  • 检测样本量增加:2012年2,201例患者(2,278个肿瘤) vs 2014年2,558例患者(2,659个肿瘤)。
  • HER2阳性率保持恒定:2012年15.7% vs 2014年15.5%。
  • 6个月内重复检测数增加超过一倍:2012年122/2,201(5.5%) vs 2014年302/2,558(11.8%)(P < .001)。
  • IHC 2+肿瘤比例显著降低:2012年25.3% vs 2014年20.3%(P < .001)。
  • 未明确HER2状态(IHC和原位杂交均为不确定)患者比例显著升高:2012年4/2,278 vs 2014年90/2,660(P < .001)。

关键数值与推荐

  • 2013年更新未影响总体HER2阳性率(15.7% vs 15.5%)或适合HER2靶向治疗的患者比例。
  • IHC 2+肿瘤比例显著降低(20.3% vs 25.3%;P < .001)。
  • 未明确HER2状态患者比例显著升高(4/2,278 vs 90/2,660;P < .001)。
  • 6个月内重复检测数增加超过一倍(122/2,201 [5.5%] vs 302/2,558 [11.8%];P < .001)。

临床怎么用

  • 原文结论指出,不确定组靶向治疗的获益未被证实,因此不应考虑对该类患者进行靶向治疗。
  • 原文建议,该不确定类别应在未来指南更新中重新定义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To study the effect of the 2013 updates to the 2007 American Society of Clinical Oncology/College of American Pathologists recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer on testing patterns and interpretation in a large regional reference laboratory. Patients and Methods Patient cases with HER2 testing scores for breast biomarker evaluation were selected from our laboratory information system during two 12-month periods (2012 and 2014). The number of tests performed, type of specimens, proportion of HER2-positive and equivocal patient cases, and number of repeat tests on subsequent excisional specimens were examined and compared. Results Although the number of samples tested increased between 2012 and 2014 (2,201 v 2,558 patient cases; 2,278 v 2,659 tumors), HER2 positivity remained constant (15.7% v 15.5%, respectively). The number of repeat tests performed within 6 months more than doubled (122 [5.5%) of 2,201 v 302 [11.8%] of 2,558; P < .001), and the proportion of immunohistochemistry (IHC) 2+ tumors was significantly lower in 2014 than in 2012 (20.3% v 25.3%; P < .001). However, the proportion of patient cases with unresolved HER2 statuses (equivocal by IHC and in situ hybridization) was significantly higher in 2014 (four of 2,278 v 90 of 2,660; P < .001). Conclusion Our findings indicate that the 2013 updates to the American Society of Clinical Oncology/College of American Pathologists recommendations for HER2 testing in breast cancer did not affect the overall HER2-positivity rate or the proportion of patients eligible for HER2-targeted therapy. The proportion of tests and repeat tests performed increased, as did the number of patient cases categorized as ISH equivocal. The benefit of targeted therapy in the equivocal group is not proven, so targeted therapy should not be considered for patients in this category which should be redefined in future iterations of the recommendations.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hanna WM, Slodkowska E, Lu FI, et al. Comparative Analysis of Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer According to 2007 and 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations. J Clin Oncol. 2017. PMID: 28445098. doi:10.1200/JCO.2016.70.5319

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。